Bone marrow infusion

DRUG2 trials

Sponsors

Masonic Cancer Center, University of Minnesota, St. Jude Children's Research Hospital

Conditions

Epidermolysis BullosaHematologic MalignancyMyeloid Malignancy

Phase 2

MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs

CompletedNCT02582775

Masonic Cancer Center, University of MinnesotaEpidermolysis Bullosa

Start: 2016-03-31End: 2023-07-26Updated: 2024-09-19

Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.

TerminatedNCT05579769

St. Jude Children's Research HospitalHematologic Malignancy, Myeloid Malignancy

Start: 2023-03-14End: 2024-05-08Updated: 2025-10-02

Related Papers

Bone marrow transplant with post‐transplant cyclophosphamide for recessive dystrophic epidermolysis bullosa expands the related donor pool and permits tolerance of nonhaematopoietic cellular grafts

British Journal of Dermatology2019-03-0738 citations